|drug307||Anti-SARS-CoV-2 convalescent plasma Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
The purpose of this trial is to determine whether Prone Positioning (PP) improves outcomes for non-intubated hospitalized patients with hypoxemic respiratory failure due to COVID-19, who are not candidates for mechanical ventilation in the ICU. The investigators hypothesize that PP will reduce in-hospital mortality or discharge to hospice, compared with usual care for non-intubated patients with do-not-intubate goals of care with hypoxemic respiratory failure due to probable COVID-19.
Description: In-hospital mortality or discharge to hospice at Day 60.Measure: Hospital mortality or discharge to hospice Time: 60 days
Description: An Adverse Event (AE) is any unfavourable or other finding (including clinically significant laboratory tests), symptom or disease occurring during the during of the study, whether or not it is considered to be related to the medicinal (investigational) product, not explicitly classified elsewhere in this protocol, and whether or not it is expected. A Serious Adverse Event (AE) is any unfavourable medical finding (including clinically significant laboratory tests) at any dose that: Results in death (primary outcome) Is life threatening Results in persistent of significant disability or incapacity Requires in in-patient hospitalisation or prolongation of HospitalisationMeasure: Adverse Events and Serious Adverse Events Time: 60 days
Description: Change in SpO2 during each PP session (SpO2 in prone position - SpO2 prior to prone positioning). Clinicians will be asked to record this change for the first proning session per shift (for 12 hour shifts this will result in 2 proning sessions being documented per 24 hour period, and for 8 hour shifts this will result in 3 proning sessions being documented per 24 hour period).Measure: Change in SpO2 Time: 60 days
Description: Number of hospital free days in the 60 days after enrolment.Measure: Hospital free days Time: 60 days
Description: Admission to the Intensive Care Unit.Measure: Admission to ICU Time: 60 days
Description: Patient is intubated and requires mechanical ventilation.Measure: Intubation and mechanical ventilation Time: 60 days
Description: Patient requires non-invasive ventilation (NIV) or high-flow nasal oxygen (HFNO).Measure: Initiation of non-invasive ventilation (NIV) or high-flow nasal oxygen (HFNO). Time: 60 days
Description: The number of oxygen-free days at Day 60 (censored at discharge).Measure: Oxygen-free days Time: 60 days
Description: Time from admission to all-cause in-hospital death.Measure: In-hospital death (time) Time: 60 days
Description: Death at 90 days.Measure: Death at 90 days Time: 90 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports